TFX - Teleflex Incorporated
246.32 +0.39 (0.16%)
After hours: 4:26PM EST
| Previous Close | 245.75 |
| Open | 247.35 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's Range | 244.85 - 248.74 |
| 52 Week Range | 227.52 - 288.78 |
| Volume | 189,369 |
| Avg. Volume | 307,822 |
| Market Cap | 11.308B |
| Beta (3Y Monthly) | 1.32 |
| PE Ratio (TTM) | 169.14 |
| EPS (TTM) | 1.45 |
| Earnings Date | Feb 20, 2019 - Feb 25, 2019 |
| Forward Dividend & Yield | 1.36 (0.53%) |
| Ex-Dividend Date | 2018-11-14 |
| 1y Target Est | 300.30 |
- Business Wire•yesterday
Employees Ranked Teleflex as a Best Place to Work
For the second year in a row, Teleflex earned a top spot as a best place to work by US sales professionals in the annual MedReps.com Best Places to Work Survey. Teleflex Incorporated (TFX), a leading global provider of medical technologies for critical care and surgery, announced that it was named the winner of MedReps.com’s 8th Annual Best Places to Work 2019 survey for the Large Category Best Medical Device Companies and came in second in the Overall Category, covering Best Medical Device Companies, Best Pharma Companies and Best Biotech Companies. Positive culture, strong products and innovation, opportunities for growth, trustworthiness in their leaders and collaboration were among the top factors cited by survey participants when asked why a company should be named the best place to work.
- Simply Wall St.•4 days ago
Is Teleflex Incorporated (NYSE:TFX) Worth US$256 Based On Intrinsic Value?
In this article I am going to calculate the intrinsic value of Teleflex Incorporated (NYSE:TFX) by taking the expected future cash flows and discounting them to their present value. This Read More...
- Business Wire•4 days ago
12-Month Results from Study of NeoTract’s UroLift® System for BPH in Men with an Obstructive Median Lobe Published in Prostate Cancer and Prostatic Diseases
NeoTract, a wholly owned subsidiary of Teleflex Incorporated (TFX) focused on addressing unmet needs in the field of urology, today announced the publication of 12-month data from the multi-center prospective MedLift™ Study of the UroLift® System treatment for Benign Prostatic Hyperplasia (BPH) in patients with an obstructive median lobe. Results were published in Prostate Cancer and Prostatic Diseases, a Nature Publishing Group journal.
- Business Wire•8 days ago
Teleflex Announces Expanded “Family-Friendly” Benefits Beginning January 1, 2019 to Meet the Diverse Needs of Its Employees
Child-Bearer Parental Leave Support expanded by 300%, from 6 Weeks to 18 Weeks
- Insider Monkey•10 days ago
Hedge Funds Are Dumping Teleflex Incorporated (TFX)
Before we spend many hours researching a company, we’d like to analyze what insiders, hedge funds and billionaire investors think of the stock first. We would like to do so because the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of […]
- Zacks•17 days ago
Teleflex (TFX) Up 4.5% Since Last Earnings Report: Can It Continue?
Teleflex (TFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire•19 days ago
Report: Developing Opportunities within Teleflex, Anthem, Crown Castle International, MSCI, GCI Liberty, and Akebia Therapeutics — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 29, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Markit•last monthSee what the IHS Markit Score report has to say about Teleflex Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Business Wire•last month
NeoTract Announces Japanese Regulatory Approval for UroLift® System for Treatment of Enlarged Prostate
NeoTract, a wholly owned subsidiary of Teleflex Incorporated (TFX) focused on addressing unmet needs in the field of urology, today announced the Company has received Shonin approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for the UroLift® System for the treatment of benign prostatic hyperplasia (BPH). If BPH is left untreated, the condition can worsen over time and cause permanent bladder damage. The Company estimates there are about 2.3 million men age 50 and older in Japan who have been diagnosed with BPH1.
- Zacks•2 months ago
Teleflex (TFX) Q3 Earnings Surpass Estimates, EPS View Up
Teleflex (TFX) consistently rides high on a robust uptick in revenues, backed by stable segmental growth and solid geographical expansions.
Motley Fool•2 months agoTeleflex Inc. (TFX) Q3 2018 Earnings Conference Call Transcript
TFX earnings call for the period ending September 30, 2018.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of TFX earnings conference call or presentation 1-Nov-18 12:00pm GMT
Q3 2018 Teleflex Inc Earnings Call
- Associated Press•2 months ago
Teleflex: 3Q Earnings Snapshot
The Wayne, Pennsylvania-based company said it had net income of $1.21 per share. Earnings, adjusted for amortization costs and restructuring costs, were $2.52 per share. The results topped Wall Street ...
- Business Wire•2 months ago
Teleflex Announces Quarterly Dividend
Teleflex Incorporated announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents per share of common stock. The dividend is payable December 14, 2018 to shareholders of record at the close of business on November 15, 2018.
- Business Wire•2 months ago
Teleflex Reports Third Quarter 2018 Results
Third Quarter Revenues of $609.7 million, up 14.0% Versus Prior Year Period; up 15.0% on Constant Currency Basis
- Business Wire•2 months ago
Teleflex to Present at the Credit Suisse 27th Annual Healthcare Conference
Liam Kelly, President and CEO, Teleflex Incorporated , is scheduled to speak at the Credit Suisse 27th Annual Healthcare Conference at The Phoenician in Scottsdale, AZ, Wednesday, November 14, 2018 at 11:30 a.m.
- Business Wire•2 months ago
Teleflex Receives 2018 Medical Design Excellence Award (MDEA) for Arrow® AC3 OptimusTM Intra-Aortic Balloon Pump
Teleflex Incorporated (TFX), a leading global provider of medical technologies for critical care and surgery, is proud to announce the Arrow AC3 Optimus Intra-Aortic Balloon Pump, has been selected as the bronze winner in the cardiovascular device category of the 20th annual Medical Design Excellence Awards competition. The AC3 Optimus IABP helps a weakened heart pump blood and can deliver IABP therapy to a broad range of patients, even those not previously considered candidates for IABP therapy.
- Business Wire•2 months ago
NeoTract Receives Phoenix 2018 Emerging Growth Company Award for Outstanding Industry Achievement
NeoTract, a wholly owned subsidiary of Teleflex Incorporated (TFX) focused on addressing unmet needs in the field of urology, today announced the company received the Phoenix 2018 Emerging Growth Company Award at the 25th Annual Phoenix Medical Device and Diagnostic Conference in Laguna Beach, Calif. sponsored by the firm Wilson Sonsini Goodrich & Rosati. The Emerging Growth Company award is presented to an organization that has undergone a strategically significant merger, a highly successful IPO, dramatic growth in sales, or the creation of a major new product or service. Last year, NeoTract was acquired by Teleflex Incorporated in a transaction valued at up to $1.1 billion.
- Business Wire•2 months ago
NeoTract Welcomes UK Government Announcement to Remove Barriers to Adoption of the UroLift® System for BPH Care for Every NHS Hospital in England
The UroLift System will now benefit from support from the Accelerated Access Collaborative to rapidly increase its uptake in the NHS. Neil Barber, Consultant Urologist, Frimley Health NHS Foundation Trust, was the first surgeon to routinely offer the UroLift System on the NHS. Having been involved in the initial European randomized clinical trial, the potential benefits of the UroLift System to both patients and the NHS quickly became very clear.
- Business Wire•2 months ago
NeoTract Welcomes UK Government Announcement to Remove Barriers to Adoption of the UroLift® System for BPH Care for Every NHS Hospital in England
The UroLift System will now benefit from support from the Accelerated Access Collaborative to rapidly increase its uptake in the NHS. Neil Barber, Consultant Urologist, Frimley Health NHS Foundation Trust, was the first surgeon to routinely offer the UroLift System on the NHS. Having been involved in the initial European randomized clinical trial, the potential benefits of the UroLift System to both patients and the NHS quickly became very clear.
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind Teleflex, Loral Space and Communications, MSCI, Mid-America Apartment Communities, Huntington Ingalls Industries, and Korea Electric Power — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•2 months ago
Teleflex Announces Third Quarter 2018 Earnings Conference Call Information
Live Webcast is scheduled at 8:00 a.m. on Thursday, November 1, 2018
- Business Wire•2 months ago
NeoTract Announces Data from New Real-World Study Demonstrating Excellent Results for UroLift® System Treatment for Enlarged Prostate
NeoTract, a wholly owned subsidiary of Teleflex Incorporated (TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the 2018 Annual Meeting of the Northeastern Section of the American Urology Association (AUA) in Toronto, Ontario, from a study of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH). The real-world study, which enrolled 100 patients at a single center, evaluated the UroLift System treatment for lower urinary tract symptoms (LUTS) in men with BPH.
Markit•2 months agoSee what the IHS Markit Score report has to say about Teleflex Inc.
To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•2 months ago
Teleflex's Latest Essential Medical Buyout to Broaden Suite
Teleflex (TFX) acquires Essential Medical to strengthen hold in the high-potential structural heart and endovascular aneurysm repair markets.
